摘要
目的观察香菇多糖(LNT)注射液联合长春瑞滨+奥沙利铂(NP方案)治疗晚期非小细胞肺癌(NSCLC)的近期疗效和不良反应。方法78例经临床病理学或细胞学证实的晚期NSCLC患者分为对照组(NP方案)和观察组(LNT联合NP方案)。对照组应用长春瑞滨25~30mg/m2第1、8天,奥沙利铂130mg/m2总量均分后于第1~3天静脉滴注;观察组在此基础上加用香菇多糖注射剂1mg,每周2次静脉滴注;21天为1周期,完成2~4周期后进行疗效测评。结果对照组:部分缓解(PR)46.2%(12/26),稳定(SD)30.8%(8/26),进展(PD)23.1%(6/26),总有效率为46.1%;观察组:PR50.0%(26/52),SD42.3%(22/52),PD7.7%(4/52),总有效率为50.0%,近期疗效差异无统计学意义(P>0.05)。临床受益反应:观察组治疗后KPS评分增加>20分者占76.9%;体质量增加者>7%,占57.6%,止痛药用量减少50%者,占42.3%,而对照组则分别为38.4%、30.7%和38.4%,二者差异有统计学意义(均P<0.05)。观察组不良反应主要为轻微的血液学毒性。结论香菇多糖注射剂联合NP方案化疗具有改善生活质量和明显协同、增效、减毒作用,不良反应作用轻微,可以作为化疗的重要辅助用药。
Objective To evaluate the short-term therapeutic and adverse effect of lentinan and venorelbine and oxaliplatin regimen recombination on patients with advanced non-small cell lung cancer(NSCLC). Methods Seventyeight advanced NSCLC cases diagnosed by clinical pathology or cellular biopsy were divided into control group treated with venorelbine +oxaliplatin(NP) regimen and observation group treated with lentinan and NP recombination. The usage of NP was venorelbine (25-30 mg/m^2 , d1,d8)combined with oxaliplatin (130 mg/m^2 ,equally divided into d1- 3),for intravenous use in control group;Based on the above,in observation group,lentinan was administered by 1 mg, twice a week intravenously. The chemotherapy interval was 21 days,and the clinical therapeutic and adverse effect were assessed after 2 to 4 cycles. Results Partial remission(PR),stabilization(SD),progression of disease(PD) and overall response rates(CR+PR) in control group were as follows.. PR 46.2% (12/26), SD 30. 8% (8/26), PD 23. 1% (6/26), CR+PR 46.1% ;while those of observation group: PR 50.0% (26/52), SD 42.3% (22/52) ,PD 7.7% (4/52) ,CR+ PR 50.0% ,the variance of short-term therapeutic effect had no statistic significance( P 〈0.05). As for clinical benefit response(CBR) ,observation group showed that the scores of Karnafsky Performance Status(KPS)〉20 accounted for 76.9 %0 ,body mass augmentation 〉 7 %, accounted for 57.6 %, and anodyne usage reduction of 50.0% accounted for 42.3 % ;those of control group were 38.4 %, 30.7 %, 38.4 % (all P〈 0.05). The major adverse reaction of observation group was mild hematologic toxicity. Conclusion Lentinan combined with venorelbine and oxaliplatin regimen can ameliorate life quality and has the effect of synergism and mild adverse reaction on chemotherapy for patients with advanced NSCLC. So lentinan can become an important remedy adjuvant of chemotherapy.
出处
《临床荟萃》
CAS
2009年第6期501-504,共4页
Clinical Focus
关键词
癌
非小细胞肺
香菇多糖
药物疗法
联合
carcinama, non-small-cell-lung
lentinan
drug therapy, combination